Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02151448 · OUTCOME

Overall Survival (OS)

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies · Source last updated 2020-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 5 years

What was measured

The length of time from the start of treatment that diagnosed patients are still alive.

Analysis population: Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery.

Groups in this outcome

α DC1 Vaccine + Chemokine Modulatory Regimen

α DC1 vaccine and Chemokine Modulatory Regimen: Celecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\^2 or 20 MU/m\^2 (T-Fri)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
α DC1 Vaccine + Chemokine Modulatory Regimen64

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
α DC1 Vaccine + Chemokine Modulatory Regimen52Not reported44NAUpper bound of 95% CI not reached.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Upper bound of 95% CI not reached.
        group Id
        OG000
        lower Limit
        44
        upper Limit
        NA
        value
        52
denoms
  1. counts
    1. group Id
      OG000
      value
      64
    units
    Participants
description
The length of time from the start of treatment that diagnosed patients are still alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    α DC1 vaccine and Chemokine Modulatory Regimen: Celecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\^2 or 20 MU/m\^2 (T-Fri)
    id
    OG000
    title
    α DC1 Vaccine + Chemokine Modulatory Regimen
param Type
MEDIAN
population Description
Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery.
reporting Status
POSTED
time Frame
Up to 5 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice